These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36123621)

  • 1. Joint models for dynamic prediction in localised prostate cancer: a literature review.
    Parr H; Hall E; Porta N
    BMC Med Res Methodol; 2022 Sep; 22(1):245. PubMed ID: 36123621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial.
    Parr H; Porta N; Tree AC; Dearnaley D; Hall E
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1055-1068. PubMed ID: 36822374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illustration of association between change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach.
    Liaqat M; Kamal S; Fischer F
    BMC Urol; 2023 Dec; 23(1):202. PubMed ID: 38057759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
    Proust-Lima C; Taylor JM
    Biostatistics; 2009 Jul; 10(3):535-49. PubMed ID: 19369642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer.
    Ferrer L; Rondeau V; Dignam J; Pickles T; Jacqmin-Gadda H; Proust-Lima C
    Stat Med; 2016 Sep; 35(22):3933-48. PubMed ID: 27090611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial.
    Finelli A; Beer TM; Chowdhury S; Evans CP; Fizazi K; Higano CS; Kim J; Martin L; Saad F; Saarela O
    JAMA Netw Open; 2021 Jun; 4(6):e2112426. PubMed ID: 34129025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
    Riglet F; Mentre F; Veyrat-Follet C; Bertrand J
    AAPS J; 2020 Feb; 22(2):50. PubMed ID: 32076894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint latent class models for longitudinal and time-to-event data: a review.
    Proust-Lima C; Séne M; Taylor JM; Jacqmin-Gadda H
    Stat Methods Med Res; 2014 Feb; 23(1):74-90. PubMed ID: 22517270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.
    Sutcliffe P; Hummel S; Simpson E; Young T; Rees A; Wilkinson A; Hamdy F; Clarke N; Staffurth J
    Health Technol Assess; 2009 Jan; 13(5):iii, xi-xiii 1-219. PubMed ID: 19128541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
    Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
    BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
    Desmée S; Mentré F; Veyrat-Follet C; Sébastien B; Guedj J
    BMC Med Res Methodol; 2017 Jul; 17(1):105. PubMed ID: 28716060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation.
    Sène M; Taylor JM; Dignam JJ; Jacqmin-Gadda H; Proust-Lima C
    Stat Methods Med Res; 2016 Dec; 25(6):2972-2991. PubMed ID: 24847900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
    Vickers AJ; Savage C; O'Brien MF; Lilja H
    J Clin Oncol; 2009 Jan; 27(3):398-403. PubMed ID: 19064972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
    Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
    J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time individual predictions of prostate cancer recurrence using joint models.
    Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
    Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
    Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
    BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.